Generic Drug News and Research RSS Feed - Generic Drug News and Research

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.
Study on cancer care offers model for possible lower spending on treatment

Study on cancer care offers model for possible lower spending on treatment

The study, however, raised some questions because while it cut costs by a third and showed no decline in patient health, the spending on chemotherapy medications rose. [More]
First Edition: June 9, 2014

First Edition: June 9, 2014

Today's headlines include a status report on GOP discussions and debate over plans to replace the health law as well as coverage of emerging legislation to override the Supreme Court's Hobby Lobby decision. [More]
USA witnesses dramatic slowdown in health spending growth over last decade

USA witnesses dramatic slowdown in health spending growth over last decade

Growth in health expenditure in the USA slowed dramatically between 2000 and 2011, bringing the growth rate of the country’s health budget in line with other high-spending countries, according to new research published in The Lancet as part of a new Series, The health of Americans. [More]
Concerns rise about delays in getting generic drugs to market

Concerns rise about delays in getting generic drugs to market

PBS NewsHour explores concerns that settlements on patents for drugs sometimes delay the generic version getting to consumers. [More]
Generic drug delays cost U.S. payers millions

Generic drug delays cost U.S. payers millions

Problems surrounding an Indian company's launch of generic versions of three blockbuster drugs have preserved millions in revenue for the brand-name makers, reports The Wall Street Journal. [More]
Walgreens reports May sales of $6.57 billion

Walgreens reports May sales of $6.57 billion

Walgreens had May sales of $6.57 billion, an increase of 6.0 percent from $6.19 billion for the same month in fiscal 2013. [More]
Teva Pharmaceutical Industries enters into definitive agreement to acquire Labrys

Teva Pharmaceutical Industries enters into definitive agreement to acquire Labrys

Teva Pharmaceutical Industries Ltd., and Labrys Biologics, Inc., a privately-held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, today announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva's array of biotechnology assets and capabilities. [More]
U.S. Court awards Teva favorable decision for generic Celebrex

U.S. Court awards Teva favorable decision for generic Celebrex

Teva Pharmaceutical Industries Ltd. announced that the U.S. District Court for the Northern District of West Virginia denied a motion filed by Mylan and issued an opinion and order affirming a decision by the FDA under which Teva should receive sole 180-day "first-to-file" exclusivity for generic Celebrex® (celecoxib) 100, 200 and 400 mg capsules. [More]
TEVA presents results from real-life, observational study of QVAR at ATS 2014 International Conference

TEVA presents results from real-life, observational study of QVAR at ATS 2014 International Conference

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced that results from a real-life, retrospective, observational study of QVAR- will be presented at the American Thoracic Society (ATS) 2014 International Conference in San Diego on May 18, 2014. [More]
First Edition: May 16, 2014

First Edition: May 16, 2014

Today's headlines include reports about the Indiana governor's alternative plan to expand Medicaid. Kaiser Health News staff writer Sarah Varney, working in collaboration with PBS Newshour, reports: "Men and women involved in the criminal justice system are more likely to be sicker than the general population, with higher rates of diabetes, hypertension, depression, mood disorders and alcohol and drug addiction. [More]
Pharmaceutical Executive Magazine names COPAXONE therapy as 2014 "Brand of The Year"

Pharmaceutical Executive Magazine names COPAXONE therapy as 2014 "Brand of The Year"

Teva Pharmaceutical Industries Ltd., today announced that COPAXONE (glatiramer acetate injection), the #1 global therapy for relapsing multiple sclerosis, has been named the 2014 "Brand of The Year" by Pharmaceutical Executive Magazine, a leading print and online publication for the biopharmaceutical industry. [More]
Concise analysis of global disposable gloves market

Concise analysis of global disposable gloves market

MRRBIZ includes new market research report "Disposable Gloves Market For Medical and Non-Medical (Food, Cleanroom, Industrial And Other) Applications - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2013 - 2019" to its large collection of research report. [More]
Teva's SYNRIBO for injection receives FDA approval for home administration

Teva's SYNRIBO for injection receives FDA approval for home administration

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous use, to include home administration, and also approved a related Medication Guide and Instructions for Use. [More]

Cambrex sales decrease by 11.2% in first quarter 2014

Cambrex Corporation reports results for the first quarter ended March 31, 2014. [More]
CVS Caremark net revenues increase 6.3% to $32.7 billion in Q1 2014

CVS Caremark net revenues increase 6.3% to $32.7 billion in Q1 2014

CVS Caremark Corporation today announced operating results for the three months ended March 31, 2014. [More]
Teva announces positive results from pivotal Phase III study of hydrocodone bitartrate extended-release tablets

Teva announces positive results from pivotal Phase III study of hydrocodone bitartrate extended-release tablets

Teva Pharmaceutical Industries Ltd. today announced positive results from a pivotal Phase III study of hydrocodone bitartrate extended-release tablets designed with Teva's proprietary technology providing potential abuse-deterrent properties (CEP-33237). [More]
Teva's DuoResp Spiromax receives EC marketing authorization for treatment of asthma, COPD

Teva's DuoResp Spiromax receives EC marketing authorization for treatment of asthma, COPD

Teva Pharmaceutical Industries Ltd., announced today that the European Commission has granted marketing authorization for DuoResp Spiromax for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD) where the use of a combination of an inhaled corticosteroid and long-acting beta2-adrenoceptor agonist is appropriate. [More]
Mylan challenges FDA's decision regarding generic drug marketing exclusivity on Celecoxib Capsules

Mylan challenges FDA's decision regarding generic drug marketing exclusivity on Celecoxib Capsules

Mylan Inc. today announced that it has filed suit against the U.S. Food and Drug Administration, challenging the agency's decision regarding generic drug marketing exclusivity on Celecoxib Capsules, the generic version of Pfizer's Celebrex. [More]
Rite Aid's fourth quarter revenues increase 2.2% to $6.6 billion

Rite Aid's fourth quarter revenues increase 2.2% to $6.6 billion

Rite Aid Corporation today reported operating results for its fourth quarter and fiscal year ended March 1, 2014. [More]
FDA approves Teva Pharmaceutical's Generic Lovaza Capsules

FDA approves Teva Pharmaceutical's Generic Lovaza Capsules

Teva Pharmaceutical Industries Ltd. announces the approval of the generic equivalent to Lovaza® (Omega-3-Acid Ethyl Esters Capsules, USP), in the United States. [More]